Influenza A/H5N1

Phase 1Biologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

Influenza A/H5N1 is one of 25 biologic programs targeting Influenza. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

Avian InfluenzaActive, not recruiting

InfluenzaPreclinical

Active, not recruiting

Avian InfluenzaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Trexall

Alnylam Pharmaceuticals

Preclinical

1 3

Crestor

AstraZeneca

Preclinical

1 4

Avigan

AAppili Therapeutics Inc.

Preclinical

6 5

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 6

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

14 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Afluria

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

MF-59

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza14 trials

Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00240903·37 enrolled

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04978454·60 enrolled

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02251288·62 enrolled

Show 11 more trials

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00992836·155 enrolled

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03058692·120 enrolled

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT02385123·60 enrolled

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00546585·126 enrolled

Inactivated Influenza A/H5N1 Vaccine in the Elderly

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00230750·261 enrolled

Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00133471·96 enrolled

Development of Childhood Anti-Influenza Immunity

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT03673345·125 enrolled

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT02485639·27 enrolled

Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00992017·130 enrolled

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01746082·211 enrolled

Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00311727·339 enrolled

Adult4 trials

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01942265·980 enrolled

A/H5N1in Adult - Aventis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00115986·452 enrolled

H5N1 With or Without Topical Aldara in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03472976·50 enrolled

Show 1 more trial

H7N9 Mix and Match With MF59 in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01938742·700 enrolled

Children2 trials

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00133536·157 enrolled

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children

Withdrawn·UUniversity of Rochester·Phase 4·NCT01097941

Virus1 trial

H1N1v Virus Challenge Study in Healthy Subjects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04044352·76 enrolled

Immunogenicity1 trial

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05755620·50 enrolled

7 more indications

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Influenza A/H5N1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Influenza A/H5N1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Influenza A/H5N1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Influenza A/H5N1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza14 trials

Adult4 trials

Children2 trials

Virus1 trial

Immunogenicity1 trial

Elderly Person1 trial

Vaccination1 trial

Pediatric1 trial

Adjuvant1 trial

Avian Influenza1 trial

Flu Vaccine1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News